Explore 2-year data from a JAKi in GCA 👀 Dr. Dua and Dr. Boone discuss remission, flares, glucocorticoid use, and safety outcomes from the Phase 3 trial of a JAKi in GCA. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/Wuu7xe5Xbl https://t.co/A4U5UX8cLd

PROSPERO meta-analysis shows an effect of diet on #RA risk. 8 independent studies (n=270,121) showed a reduced risk of incident RA with Anti-inflammatory (OR 0.56; 0.31–0.99), Mediterranean (OR 0.88; 0.78–0.99), and HEI (OR 0.60; 0.25–1.47), but not DASH diets https://t.co/qf4kTVyJ0m

Retrospective cohort study adult RA patients shows that TRIPLE Positivity (RF + /ACPA + /ANA +) was consistently associated with higher disease activity at baseline and 12 months of follow-up and lower rates of sustained remission compared to RF + /ACPA + /ANA- https://t.co/l2TQDShFYi

Did you miss RheumNow Live 2025? 👀 Don’t make the same mistake twice. 🔥 RNL 2026 Early Bird Registration is LIVE — now through Dec 1. Where clinical science meets real-world rheum talk. 🎟️ https://t.co/zYYC2350tE https://t.co/uZUlqScSm5

No risk of MACE seen w/ initiation of IL-17(R)A inhib. French study of 34 241 ipts Rx IL-17(R)Ai and 381 MACEs. MACE risk was not elevated (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitors. https://t.co/WcjgRhr8mj https://t.co/Gp54eLlXSI

A JAKi in GCA: 2-year efficacy and safety results in a Phase 3 study Discover how continued treatment with a JAKi impacted disease remission and steroid use. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/Tm8m43ZXBM https://t.co/9wkIZ9e0Gt

APEX Study: Inhibition of structural damage progression with Guselkumab in PsA Guselkumab, a human IL-23 inhibitor, was evaluated in patients with active PsA and shown to have both clinical and radiographic benefits at weeks 24 and 48. https://t.co/iNEziysnVZ https://t.co/XgFGFfGf3b

Pulse Steroids and Mycophenolate in Juvenile Dermatomyositis JAMA Dermatology has published a pilot study demonstrating the safety and efficacy of intermittent intravenous methylprednisolone pulse (IVMP) therapy plus mycophenolate in 28 patients with JDM. https://t.co/i2HBycbWY9

Rheumatology Supply and Demand (2009 - 2024) A retrospective review of US rheumatology manpower and training from 2009- ‘24 shows that US rheumatology training has become competitive, with an increasing surplus of applicants compared to available training positions. https://t.co/2yWZt8eeEJ

Target emulation trial of 12,145 Pts (87% female; age 80 yrs), shows that compared to teriparatide, Rx w/ romosozumab was assoc w/ significantly lower risk of osteoarthritis (RR 0.79); especially for knee OA (0.79). https://t.co/nEdENoNae7 https://t.co/JiyRd6ThXu